Affluent Medical
ISIN: FR0013333077 | Ticker: AFME | LEI: 969500N30CO4B5N2GN67
Country: France
ffluent Medical is committed to offering the best available therapies worldwide for hitherto largely unmet needs in terms of widespread and critical diseases. Millions of patients around the world are suffering and cannot always find optimal therapies.
Affluent Medical focuses on breakthrough medical devices using a new approach. Deep understanding of the physiology helps us to design a new generation of minimally invasive prostheses with the aim of mimicking anatomy and restoring native physiology for critical functions.
Our approach heralds a new era for cardiovascular and urological therapies. The combination of our highly talented team and deep expertise will enable us to lead this major shift toward more physiological therapies.
Affluent Medical reached in 2020 another key milestone of its development ; all its products are now in a clinical phase.
2011
Headcount48
HeadquartersLes Pléiades III - Bâtiment B 320 Avenue Archimède, 13100 Aix-en-Provence – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 64,826,000.00 | 70,035,000.00 |
| Noncurrent Assets | N/A | 56,915,000.00 | 55,360,000.00 |
| Goodwill | N/A | 32,203,000.00 | 32,203,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 22,566,000.00 | 20,695,000.00 |
| Investment Accounted For Using Equity Method | N/A | 14,000.00 | 0.00 |
| Other Noncurrent Financial Assets | N/A | 351,000.00 | 457,000.00 |
| Current Assets | N/A | 7,911,000.00 | 14,675,000.00 |
| Other Current Receivables | N/A | 2,261,000.00 | 3,265,000.00 |
| Cash and cash equivalents | N/A | 5,650,000.00 | 11,410,000.00 |
| Equity And Liabilities | N/A | 64,826,000.00 | 70,035,000.00 |
| Equity | 30,964,000.00 | 35,290,000.00 | 43,535,000.00 |
| Issued Capital | N/A | 15,257,000.00 | 18,164,000.00 |
| Retained Earnings | N/A | -42,649,000.00 | -55,207,000.00 |
| Share Premium | N/A | 62,683,000.00 | 80,546,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 35,290,000.00 | 43,535,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 |
| Noncurrent Liabilities | N/A | 19,771,000.00 | 19,197,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 117,000.00 | 96,000.00 |
| Other Longterm Provisions | N/A | 228,000.00 | 130,000.00 |
| Deferred Tax Liabilities | N/A | 2,440,000.00 | 1,973,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | 0.00 | 0.00 |
| Other Noncurrent Liabilities | N/A | 7,000.00 | N/A |
| Longterm Borrowings | N/A | 16,248,000.00 | 16,085,000.00 |
| Current Liabilities | N/A | 9,765,000.00 | 7,303,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 2,352,000.00 | 1,793,000.00 |
| Current Derivative Financial Liabilities | N/A | 1,351,000.00 | 310,000.00 |
| Other Current Liabilities | N/A | 2,261,000.00 | 2,447,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Other Income | 824,000.00 | 1,451,000.00 |
| Raw Materials And Consumables Used | 3,108,000.00 | 2,518,000.00 |
| Employee Benefits Expense | 4,694,000.00 | 4,405,000.00 |
| Depreciation And Amortisation Expense | 1,907,000.00 | 2,420,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 125,000.00 | -98,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 125,000.00 | -98,000.00 |
| Tax Expense Other Than Income Tax Expense | 67,000.00 | 88,000.00 |
| Other Expense By Nature | 3,563,000.00 | 5,496,000.00 |
| Profit Loss From Operating Activities | -12,992,000.00 | -13,247,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -398,000.00 | -14,000.00 |
| Profit Loss Before Tax | -14,528,000.00 | -15,257,000.00 |
| Income Tax Expense Continuing Operations | -209,000.00 | -437,000.00 |
| Profit (loss) | -14,319,000.00 | -14,820,000.00 |
| Profit Loss Attributable To Owners Of Parent | -14,319,000.00 | -14,820,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 |
| Line item in (eur) | 01.01.2021 | 01.01.2022 |
|---|---|---|
| Profit (loss) | -14,319,000.00 | -14,820,000.00 |
| Adjustments For Income Tax Expense | -209,000.00 | -437,000.00 |
| Adjustments For Finance Costs | 2,039,000.00 | 3,037,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | 1,728,000.00 | -1,002,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | -1,352,000.00 | -558,000.00 |
| Adjustments For Sharebased Payments | 959,000.00 | 42,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | 0.00 | -20,000.00 |
| Cash Flows From Used In Operating Activities | -8,936,000.00 | -12,364,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 304,000.00 | 334,000.00 |
| Cash Flows From Used In Investing Activities | -304,000.00 | -160,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 2,140,000.00 | 795,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 222,000.00 | 283,000.00 |
| Proceeds From Government Grants Classified As Financing Activities | 2,755,000.00 | 2,529,000.00 |
| Interest Paid Classified As Financing Activities | 715,000.00 | 521,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | 0.00 | -500,000.00 |
| Cash Flows From Used In Financing Activities | 12,762,000.00 | 18,281,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 0.00 | 0.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 3,522,000.00 | 5,757,000.00 |
| Cash and cash equivalents | 5,650,000.00 | 11,410,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 06.03.23 | None | Other | Other | EUR 8,399,204.88 |
| 06.03.23 | None | Other | Other | EUR 190,891.02 |
FR0013333077
LEI969500N30CO4B5N2GN67
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.